Brind.

MaxCyte provided its platform technology to Anocca AB, which will use the technology for manufacturing.

1 report, 1 independent Updated Jul 31
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

MaxCyte provided its platform technology to Anocca AB, which will use the technology for manufacturing.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireMaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the ma